AGÕæÈ˹ٷ½

STOCK TITAN

[Form 4] HilleVax, Inc. Insider Trading Activity

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
4
Rhea-AI Filing Summary

HilleVax, Inc. (HLVX) â€� Form 4 insider transaction

Director Aditya Kohli reported two equity movements dated 23 June 2025:

  • Grant of 17,199 Restricted Stock Units (RSUs) at zero cost under the company’s Non-Employee Director Compensation Program. The award vests 100% on the earlier of the first anniversary of grant or a Change in Control, contingent upon continued board service.
  • Forfeiture of 83,906 unvested RSUs that were not subject to acceleration following Kohli’s prior termination of employment.

Post-transaction, Kohli holds 698,171 HLVX common shares directly. No derivative securities were reported. The filing does not disclose cash consideration, option exercises, or open-market trades, and therefore carries limited valuation impact for public shareholders.

HilleVax, Inc. (HLVX) � Transazione interna Form 4

Il direttore Aditya Kohli ha segnalato due movimenti azionari datati 23 giugno 2025:

  • Assegnazione di 17.199 Restricted Stock Units (RSU) a costo zero nell’ambito del Programma di Compensazione per Direttori Non Dipendenti della società. Il premio matura al 100% alla prima delle due date: il primo anniversario della concessione o un Cambio di Controllo, subordinato alla continuità del servizio nel consiglio.
  • Perdita di 83.906 RSU non maturate che non sono state accelerate a seguito della precedente cessazione del rapporto di lavoro di Kohli.

Dopo la transazione, Kohli detiene 698.171 azioni ordinarie HLVX direttamente. Non sono stati segnalati strumenti derivati. La comunicazione non indica corrispettivi in denaro, esercizi di opzioni o operazioni sul mercato aperto, pertanto l’impatto valutativo per gli azionisti pubblici è limitato.

HilleVax, Inc. (HLVX) � Transacción interna Formulario 4

El director Aditya Kohli reportó dos movimientos de acciones fechados el 23 de junio de 2025:

  • Concesión de 17,199 Unidades de Acciones Restringidas (RSUs) sin costo bajo el Programa de Compensación para Directores No Empleados de la empresa. La adjudicación se consolida al 100% en la fecha que ocurra primero entre el primer aniversario de la concesión o un Cambio de Control, condicionado a la continuidad en el consejo.
  • Renuncia a 83,906 RSUs no consolidadas que no fueron aceleradas tras la terminación previa del empleo de Kohli.

Después de la transacción, Kohli posee 698,171 acciones comunes de HLVX directamente. No se reportaron valores derivados. La presentación no revela consideraciones en efectivo, ejercicios de opciones ni operaciones en el mercado abierto, por lo que el impacto en la valoración para los accionistas públicos es limitado.

HilleVax, Inc. (HLVX) � Form 4 내부� 거래

ì´ì‚¬ Aditya KohliëŠ� 2025ë…� 6ì›� 23ì¼ìžë¡� ë‘� 가지 ì£¼ì‹ ë³€ë™ì„ 보고했습니다:

  • 비용 ì—†ì´ ë¶€ì—¬ëœ 17,199ê°œì˜ ì œí•œ ì£¼ì‹ ë‹¨ìœ„(RSUs)ë¡�, 회사ì� 비임ì›� ì´ì‚¬ ë³´ìƒ í”„ë¡œê·¸ëž¨ì—� 따른 것입니다. ì� ë³´ìƒì€ 부여ì¼ë¡œë¶€í„� 1주년 ë˜ëŠ” ê²½ì˜ê¶� ë³€ê²� ì¤� 빠른 시ì ì—� 100% 확정ë˜ë©°, ì´ì‚¬íš� 서비ìŠ� ì§€ì†ì´ 조건입니ë‹�.
  • ì´ì „ì—� Kohliì� ê³ ìš© 종료ë¡� ì¸í•´ ê°€ì†í™”ë˜ì§€ ì•Šì€ 83,906ê°œì˜ ë¯¸í™•ì � RSUs 몰수ë˜ì—ˆìŠµë‹ˆë‹�.

거래 í›� KohliëŠ� ì§ì ‘ 보유í•� HLVX 보통ì£� 698,171ì£�ë¥� 가지ê³� 있습니다. íŒŒìƒ ì¦ê¶Œì€ ë³´ê³ ë˜ì§€ 않았습니ë‹�. 제출 서류ì—는 현금 대가, 옵션 행사 ë˜ëŠ” 공개 시장 거래ì—� 대í•� ì •ë³´ê°€ 없어 공공 주주ì—게 미치ëŠ� í‰ê°€ ì˜í–¥ì€ 제한ì ìž…니다.

HilleVax, Inc. (HLVX) � Transaction d’initié Formulaire 4

Le directeur Aditya Kohli a déclaré deux mouvements d’actions datés du 23 juin 2025 :

  • Attribution de 17 199 unités d’actions restreintes (RSU) à titre gratuit dans le cadre du programme de rémunération des administrateurs non salariés de la société. La remise s’acquiert à 100 % à la date la plus proche entre le premier anniversaire de l’attribution ou un changement de contrôle, sous réserve de la poursuite du service au conseil.
  • Perte de 83 906 RSU non acquises qui n’ont pas été accélérées suite à la précédente cessation d’emploi de Kohli.

Après la transaction, Kohli détient 698 171 actions ordinaires HLVX directement. Aucun titre dérivé n’a été signalé. Le dépôt ne révèle pas de contrepartie en espèces, d’exercice d’options ou de transactions sur le marché libre, ce qui limite l’impact en termes de valorisation pour les actionnaires publics.

HilleVax, Inc. (HLVX) � Form 4 Insider-Transaktion

Direktor Aditya Kohli meldete zwei Aktienbewegungen vom 23. Juni 2025:

  • Gewährung von 17.199 Restricted Stock Units (RSUs) kostenfrei im Rahmen des Vergütungsprogramms für nicht-angestellte Direktoren des Unternehmens. Die Zuteilung wird zu 100 % fällig am früheren Zeitpunkt zwischen dem ersten Jahrestag der Gewährung oder einem Kontrollwechsel, vorausgesetzt der Vorstandsdienst wird fortgesetzt.
  • Verfall von 83.906 nicht unverfallbaren RSUs, die nach Kohlis vorheriger Beendigung des Arbeitsverhältnisses nicht beschleunigt wurden.

Nach der Transaktion hält Kohli 698.171 HLVX-Stammaktien direkt. Es wurden keine derivativen Wertpapiere gemeldet. Die Meldung enthält keine Angaben zu Barvergütungen, Optionsausübungen oder Börsengeschäften, weshalb die Bewertungsauswirkung für öffentliche Aktionäre begrenzt ist.

Positive
  • Director equity grant reinforces alignment between board member and shareholders through performance-linked RSUs.
Negative
  • Cancellation of 83,906 unvested RSUs represents dilution avoidance but may hint at earlier executive turnover; minor oversight risk.

Insights

TL;DR: Routine director RSU grant and forfeiture; negligible effect on valuation or float.

The filing shows a standard annual equity grant (17,199 RSUs) offset by forfeiture of 83,906 previously awarded RSUs that failed to vest. Net share count impact is de-minimis relative to HilleVax’s ~40 million shares outstanding. No purchase or sale occurred, so market liquidity and insider sentiment gauges remain unchanged. I classify the event as administratively routine and not financially material.

TL;DR: Governance-aligned compensation; single-year cliff vesting, change-in-control trigger typical for biotech boards.

The RSU structure aligns director incentives with shareholder interests by tying value to future stock performance. One-year cliff vesting and acceleration on Change in Control mirror prevailing biotech governance norms. The forfeiture of unvested RSUs on employment termination demonstrates adherence to equity plan discipline. Overall, neutral governance signal with no red flags.

HilleVax, Inc. (HLVX) � Transazione interna Form 4

Il direttore Aditya Kohli ha segnalato due movimenti azionari datati 23 giugno 2025:

  • Assegnazione di 17.199 Restricted Stock Units (RSU) a costo zero nell’ambito del Programma di Compensazione per Direttori Non Dipendenti della società. Il premio matura al 100% alla prima delle due date: il primo anniversario della concessione o un Cambio di Controllo, subordinato alla continuità del servizio nel consiglio.
  • Perdita di 83.906 RSU non maturate che non sono state accelerate a seguito della precedente cessazione del rapporto di lavoro di Kohli.

Dopo la transazione, Kohli detiene 698.171 azioni ordinarie HLVX direttamente. Non sono stati segnalati strumenti derivati. La comunicazione non indica corrispettivi in denaro, esercizi di opzioni o operazioni sul mercato aperto, pertanto l’impatto valutativo per gli azionisti pubblici è limitato.

HilleVax, Inc. (HLVX) � Transacción interna Formulario 4

El director Aditya Kohli reportó dos movimientos de acciones fechados el 23 de junio de 2025:

  • Concesión de 17,199 Unidades de Acciones Restringidas (RSUs) sin costo bajo el Programa de Compensación para Directores No Empleados de la empresa. La adjudicación se consolida al 100% en la fecha que ocurra primero entre el primer aniversario de la concesión o un Cambio de Control, condicionado a la continuidad en el consejo.
  • Renuncia a 83,906 RSUs no consolidadas que no fueron aceleradas tras la terminación previa del empleo de Kohli.

Después de la transacción, Kohli posee 698,171 acciones comunes de HLVX directamente. No se reportaron valores derivados. La presentación no revela consideraciones en efectivo, ejercicios de opciones ni operaciones en el mercado abierto, por lo que el impacto en la valoración para los accionistas públicos es limitado.

HilleVax, Inc. (HLVX) � Form 4 내부� 거래

ì´ì‚¬ Aditya KohliëŠ� 2025ë…� 6ì›� 23ì¼ìžë¡� ë‘� 가지 ì£¼ì‹ ë³€ë™ì„ 보고했습니다:

  • 비용 ì—†ì´ ë¶€ì—¬ëœ 17,199ê°œì˜ ì œí•œ ì£¼ì‹ ë‹¨ìœ„(RSUs)ë¡�, 회사ì� 비임ì›� ì´ì‚¬ ë³´ìƒ í”„ë¡œê·¸ëž¨ì—� 따른 것입니다. ì� ë³´ìƒì€ 부여ì¼ë¡œë¶€í„� 1주년 ë˜ëŠ” ê²½ì˜ê¶� ë³€ê²� ì¤� 빠른 시ì ì—� 100% 확정ë˜ë©°, ì´ì‚¬íš� 서비ìŠ� ì§€ì†ì´ 조건입니ë‹�.
  • ì´ì „ì—� Kohliì� ê³ ìš© 종료ë¡� ì¸í•´ ê°€ì†í™”ë˜ì§€ ì•Šì€ 83,906ê°œì˜ ë¯¸í™•ì � RSUs 몰수ë˜ì—ˆìŠµë‹ˆë‹�.

거래 í›� KohliëŠ� ì§ì ‘ 보유í•� HLVX 보통ì£� 698,171ì£�ë¥� 가지ê³� 있습니다. íŒŒìƒ ì¦ê¶Œì€ ë³´ê³ ë˜ì§€ 않았습니ë‹�. 제출 서류ì—는 현금 대가, 옵션 행사 ë˜ëŠ” 공개 시장 거래ì—� 대í•� ì •ë³´ê°€ 없어 공공 주주ì—게 미치ëŠ� í‰ê°€ ì˜í–¥ì€ 제한ì ìž…니다.

HilleVax, Inc. (HLVX) � Transaction d’initié Formulaire 4

Le directeur Aditya Kohli a déclaré deux mouvements d’actions datés du 23 juin 2025 :

  • Attribution de 17 199 unités d’actions restreintes (RSU) à titre gratuit dans le cadre du programme de rémunération des administrateurs non salariés de la société. La remise s’acquiert à 100 % à la date la plus proche entre le premier anniversaire de l’attribution ou un changement de contrôle, sous réserve de la poursuite du service au conseil.
  • Perte de 83 906 RSU non acquises qui n’ont pas été accélérées suite à la précédente cessation d’emploi de Kohli.

Après la transaction, Kohli détient 698 171 actions ordinaires HLVX directement. Aucun titre dérivé n’a été signalé. Le dépôt ne révèle pas de contrepartie en espèces, d’exercice d’options ou de transactions sur le marché libre, ce qui limite l’impact en termes de valorisation pour les actionnaires publics.

HilleVax, Inc. (HLVX) � Form 4 Insider-Transaktion

Direktor Aditya Kohli meldete zwei Aktienbewegungen vom 23. Juni 2025:

  • Gewährung von 17.199 Restricted Stock Units (RSUs) kostenfrei im Rahmen des Vergütungsprogramms für nicht-angestellte Direktoren des Unternehmens. Die Zuteilung wird zu 100 % fällig am früheren Zeitpunkt zwischen dem ersten Jahrestag der Gewährung oder einem Kontrollwechsel, vorausgesetzt der Vorstandsdienst wird fortgesetzt.
  • Verfall von 83.906 nicht unverfallbaren RSUs, die nach Kohlis vorheriger Beendigung des Arbeitsverhältnisses nicht beschleunigt wurden.

Nach der Transaktion hält Kohli 698.171 HLVX-Stammaktien direkt. Es wurden keine derivativen Wertpapiere gemeldet. Die Meldung enthält keine Angaben zu Barvergütungen, Optionsausübungen oder Börsengeschäften, weshalb die Bewertungsauswirkung für öffentliche Aktionäre begrenzt ist.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Kohli Aditya

(Last) (First) (Middle)
C/O HILLEVAX, INC., 321 HARRISON AVE,
SUITE 500

(Street)
BOSTON MA 02118

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
HilleVax, Inc. [ HLVX ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
06/23/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 06/23/2025 A 17,199(1) A $0.00 698,171(2) D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. The Restricted Stock Units ("RSUs") were granted on June 23, 2025 pursuant to the Registrant's Non-Employee Director Compensation Program. 100% of the total number of RSUs granted shall vest on the first to occur of (i) the first anniversary of the date of grant or (ii) a Change in Control (as defined in the Registrant's 2022 Incentive Award Plan), in each case, subject to the non-employee director continuing in service on the Registrant's board of directors through such vesting date.
2. Reflects the cancellation of 83,906 RSUs. These cancelled RSUs represent the remaining outstanding and unvested RSUs awarded to the Reporting Person following their termination of employment, which were not subject to acceleration.
/s/ Paul Bavier, Attorney-in-Fact for Aditya Kohli 06/25/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

How many HLVX shares does director Aditya Kohli now own?

After the reported transactions, Kohli beneficially owns 698,171 shares of HilleVax common stock.

What was the size and cost of the new RSU grant disclosed in the Form 4?

Kohli received 17,199 RSUs at a purchase price of $0.00 per share under the Non-Employee Director Compensation Program.

When will the newly granted RSUs vest?

The RSUs vest 100% on the earlier of 23 June 2026 or a company Change in Control, provided Kohli remains on the board.

Why were 83,906 RSUs cancelled?

The RSUs were forfeited because they were unvested at the time of Kohli’s employment termination and were not eligible for acceleration.

Does this insider filing indicate a buy or sell of HLVX shares?

No cash purchase or open-market sale occurred. It reflects a non-cash RSU grant and a cancellation, making the impact on float immaterial.
HilleVax, Inc.

NASDAQ:HLVX

HLVX Rankings

HLVX Latest News

HLVX Latest SEC Filings

HLVX Stock Data

104.71M
30.11M
17.09%
76.93%
0.92%
Biotechnology
Biological Products, (no Disgnostic Substances)
United States
BOSTON